Tempus AI, Inc. - Class A Common Stock (TEM)

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA.

Ares Management Corporation (NYSEARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, Inc. NASDAQ: TEMNASDAQTEM)

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3-6, 2025, held in San Francisco, CA.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). The collaboration aims to develop and make available a real-world multimodal, deidentified FL data library in Lens - Tempus’ data analytics platform - through which researchers may derive AI-driven insights to accelerate the development of FL treatments in an effort to improve patient outcomes.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQTEM),NYSE:BBAINYSEBBAI)(NASDAQ:TALKNASDAQTALK,(NASDAQ:SOUNNASDAQ) EQNX::TICKER_END

PALM BEACH, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The growing adoption of the digital technologies in the healthcare sector owing to the growing need for reducing the healthcare costs and offer enhanced quality patient care services to the patients are the prominent factors that are boosting the growth of the global artificial intelligence in healthcare market. The surging prevalence of various chronic diseases and growing elderly population is resulting in the increased pool of patients at hospitals. The large volume of patient health data is generated every day, which is required to be stored and managed effectively. The growing demand for the personalized medicines and the necessity of maintaining digital health records are significantly driving the artificial intelligence in healthcare market. The novel technologies like artificial intelligence and machine learning are now being integrated to the healthcare systems that will allow the health professionals in early identification of the diseases and offer enhanced care services to the patients. Moreover, the data analytics, deep learning technology, natural language processing (NPL), predictive analytics, and content analytics are supporting the healthcare professionals in early diagnosis and care services. A report from Precedence Research said that the global artificial intelligence (AI) in healthcare market size accounted for USD 26.69 billion in 2024 and is predicted to reach around USD 613.81 billion by 2034, growing at a CAGR of 36.83% from 2024 to 2034. North America AI in healthcare market size reached USD 8.67 billion in 2023. Active A.I. companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQTEM), BigBear.ai NYSE: BBAINYSEBBAI)(NASDAQ: TALKNASDAQTALK, SoundHound AI, Inc. (NASDAQ: SOUNNASDAQ).

Tempus AI, Inc. (NASDAQTEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQTEM),NYSE:MDTNYSEMDT)(NYSE:TDOCNYSETDOC,(NASDAQ:TALKNASDAQ) EQNX::TICKER_END

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneously advancing research to bring new drugs to market. This latest iteration now applies Tempus’ proprietary Large Language Model (LLM) Agent Infrastructure (Agent Builder), which adapts LLMs to work on unstructured, multimodal healthcare data to improve clinical care and research.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan Healthcare on January 13-16, 2025, in San Francisco, CA.

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:CRDFNASDAQCRDF)(NASDAQ:PSNLNASDAQPSNL,(NASDAQ:TEMNASDAQ),(NASDAQ:CKPTCKPT) EQNX::TICKER_END

Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreement with Avalon, Tempus is a participating provider with BCBS North Carolina, BCBS South Carolina, BCBS Vermont, Capital BlueCross and CareSource in four markets. This enhances our work with commercial health plans in the East.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQTEM),NYSE:MDTNYSEMDT)(NYSE:SYKNYSESYK,(NASDAQ:PEGANASDAQ) EQNX::TICKER_END

PALM BEACH, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - With the advent of Artificial Intelligence (AI), the methods and techniques to diagnose have helped doctors and patients to understand these diseases in a much faster way, leading to the steady employment of AI in multiple diagnoses around the healthcare industry. The field of medical diagnostics is getting revolutionized due to AI. Medical imaging data, including X-rays, MRIs, and ultrasounds are getting analyzed by AI algorithms to help doctors discover and diagnose diseases more accurately and at a much faster rate. This can assist healthcare professionals in making better judgments regarding patient care, leading to increasing AI in diagnostics market size.   A report from Fact.MR projected that revenue from the global Artificial Intelligence in diagnostics market is projected to reach US$ 1.85 billion in 2024 and thereafter increase swiftly at a CAGR of 23.1% to end up at US$ 14.76 billion by 2034.   The report said: “Health issues are rising among people as the world goes through climate change and other environmental factors, people are getting concerned about their health thus leading to more people going to doctors for diagnosis and proper health checkups.   Medical diagnostics is a process through which doctors understand the condition of a patient's body and analyze whether the patient is suffering from any particular harmful disease. The analysis and results of these tests help doctors use the most suitable course of treatment for their patients to fight the diseases, contributing to the overall expansion of the AI in diagnostics market growth.”   Active companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQTEM), Medtronic plc NYSE: MDTNYSEMDT)(NYSE: SYKNYSESYK, Pegasystems Inc. (NASDAQ: PEGANASDAQ).

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. ECG-AF is one of just a few FDA-authorized medical technologies in the country to be impacted by the new CMS decision, and this milestone allows Tempus to more broadly support clinicians in identifying patients at increased risk of atrial fibrillation/flutter (AF).

Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis’ ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors.

EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQRXRX),NASDAQ:TEMNASDAQTEM)(NASDAQ:ISRGNASDAQISRG EQNX::TICKER_END

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York.